Related references
Note: Only part of the references are listed.CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
Andreas Gille et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression
Yanhong Guo et al.
EBIOMEDICINE (2018)
Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial A Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA CARDIOLOGY (2018)
Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr-/- Mice
Mikyung Yu et al.
ADVANCED HEALTHCARE MATERIALS (2017)
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study
Jordan Andrews et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2017)
Enhanced atheroprotection and lesion remodelling by targeting the foam cell and increasing plasma cholesterol acceptors
Se-Hee Son et al.
CARDIOVASCULAR RESEARCH (2016)
Dysfunctional HDL and atherosclerotic cardiovascular disease
Robert S. Rosenson et al.
NATURE REVIEWS CARDIOLOGY (2016)
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles
Rui Kuai et al.
ACS NANO (2016)
Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils
Todd G. Kirchgessner et al.
CELL METABOLISM (2016)
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
C. Michael Gibson et al.
CIRCULATION (2016)
Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist
Yajun Zheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of Highly Potent Liver x Receptor β Agonists
Ellen K. Kick et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Liver X receptors at the intersection of lipid metabolism and atherogenesis
Stephen D. Lee et al.
ATHEROSCLEROSIS (2015)
HDL-Mimetic PLGA Nanoparticle To Target Atherosclerosis Plaque Macrophages
Brenda L. Sanchez-Gaytan et al.
BIOCONJUGATE CHEMISTRY (2015)
Targeted Delivery of LXR Agonist Using a Site-Specific Antibody Drug Conjugate
Reyna K. V. Lim et al.
BIOCONJUGATE CHEMISTRY (2015)
Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production
Yanhong Guo et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity
Tomas Vaisar et al.
JOURNAL OF LIPID RESEARCH (2015)
The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties
Anna Schwendeman et al.
JOURNAL OF LIPID RESEARCH (2015)
HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation
Claudine Tardy et al.
PLOS ONE (2015)
Nanoparticles Containing a Liver X Receptor Agonist Inhibit Inflammation and Atherosclerosis
Xue-Qing Zhang et al.
ADVANCED HEALTHCARE MATERIALS (2015)
Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXRα Activity and a Favorable Window in Nonhuman Primates
Todd G. Kirchgessner et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Activation of Liver X Receptor Decreases Atherosclerosis in Ldlr-/-Mice in the Absence of ATP-Binding Cassette Transporters A1 and G1 in Myeloid Cells
Mojdeh S. Kappus et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
CSL112 Enhances Biomarkers of Reverse Cholesterol Transport After Single and Multiple Infusions in Healthy Subjects
Andreas Gille et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
Jean-Claude Tardif et al.
EUROPEAN HEART JOURNAL (2014)
An abundant dysfunctional apolipoprotein A1 in human atheroma
Ying Huang et al.
NATURE MEDICINE (2014)
Liver X receptors in lipid metabolism: opportunities for drug discovery
Cynthia Hong et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
Anand Rohatgi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation (vol 5, pg 3065, 2014)
Raphael Duivenvoorden et al.
NATURE COMMUNICATIONS (2014)
Reconstituted HDL for the acute treatment of acute coronary syndrome
Brian R. Krause et al.
CURRENT OPINION IN LIPIDOLOGY (2013)
Tweaking the cholesterol efflux capacity of reconstituted HDL
Cheng-I J. Ma et al.
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE (2012)
The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins
Belinda A. Di Bartolo et al.
ATHEROSCLEROSIS (2011)
Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits
Shoko Honzumi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2011)
Liver X Receptors in Atherosclerosis and Inflammation
Seung-Soon Im et al.
CIRCULATION RESEARCH (2011)
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
Amit V. Khera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cholesterol in Bilayers with PUFA Chains: Doping with DMPC or POPC Results in Sterol Reorientation and Membrane-Domain Formation
Norbert Kucerka et al.
BIOCHEMISTRY (2010)
A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice
John K. Bielicki et al.
JOURNAL OF LIPID RESEARCH (2010)
5A Apolipoprotein Mimetic Peptide Promotes Cholesterol Efflux and Reduces Atherosclerosis in Mice
Marcelo J. A. Amar et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
The liver X receptor: Control of cellular lipid homeostasis and beyond Implications for drug design
Maaike H. Oosterveer et al.
PROGRESS IN LIPID RESEARCH (2010)
High-Density Lipoprotein/Apolipoprotein A-I Infusion Therapy
Jean-Claude Tardif et al.
CURRENT ATHEROSCLEROSIS REPORTS (2009)
Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR-623, a Novel Liver X-Receptor Agonist, in Healthy Participants
Arie Katz et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation
Jenny Wong et al.
ATHEROSCLEROSIS (2008)
Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque
James A. Shaw et al.
CIRCULATION RESEARCH (2008)
The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in ApoE-/- mice
Xiao-yan Dai et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2008)
Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression
Ou Xiang et al.
SCIENCE IN CHINA SERIES C-LIFE SCIENCES (2008)
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis -: A randomized controlled trial
Jean-Claude Tardif et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages:: Evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP
I Zanotti et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
ABCA1 expression in carotid atherosclerotic plaques
C Albrecht et al.
STROKE (2004)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes - A randomized controlled trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI
PG Yancey et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Role of LXRs in control of lipogenesis
JR Schultz et al.
GENES & DEVELOPMENT (2000)
Share Paper
